This preventive drug could be a 'game changer' in ending the HIV epidemic
In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating HIV transmission during sexual contact. But its cost could be an issue.
Why Indian patients groups are opposing patent requests for blockbuster HIV drug lenacapavir
Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to affordable generics in India, warn civil society organisations.
US-based pharma giant Gilead Sciences wants HIV drug Lenacapavir patented
On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's applications, the organisation claimed.
Patent applications for HIV prevention drug opposed in India
Indian Patent Office to hear objections against Gilead's Lenacapavir patent claims, crucial for affordable HIV treatment worldwide.
Patent opposition case against Gilead’s long-acting HIV injectable drug, comes up this week
The US-based Gilead Sciences’ long-acting injectable HIV drug lenacapavir is at the centre of a patent opposition case scheduled to come up this week at the Indian Patent Office (IPO). Civil society group Sankalp Rehabilitation Trust had opposed Gilead’s patent application on the grounds that it was a known compound.
GlobalData on MSN4d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
STAT2d
Tested in Africa, used in America
The process for translating clinical trial results into action for young women in Africa has been left to our imaginations, ...
newsbytesapp.com2d
Meet Lenacapavir: The drug that could end HIV epidemic
Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...
Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against ...
infectiousdiseaseadvisor.com2d
Twice-Yearly Injectable Lenacapavir Bests Daily PrEP Tablet for HIV Prevention
Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.
Twice-yearly injection cuts HIV risk by 96%, but will cost cut access?
It could be a real breakthrough for people at risk for HIV infection: A shot given every six months that reduces their risk ...
Twice-a-year injection reduced risk of HIV infection by 96%, drug company says — more than daily PrEP pill
A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP.
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...
Buy Rating on Gilead Sciences: Underestimated Market Potential of Lenacapavir in HIV Treatment and Prevention
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...